ArticleVirchows Archiv : an international journal of pathology2022
T1 bladder carcinoma with variant histology: pathological features and clinical significance.
Article in Virchows Archiv : an international journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: a network meta-analysis.Frontiers in oncology · 2023Pooled it
- Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Variant histology in urothelial carcinoma: associated factors and survival impact after radical cystectomy.BMC urology · 2026Article
- Treatment Patterns and Radical Cystectomy Outcomes in Patients Diagnosed With Urothelial Nonmetastatic Muscle-Invasive Bladder Cancer in the United States.Cancer medicine · 2025Article
- Inflammation as a key mediator: linking triglyceride-glucose index to prognosis in non-muscle-invasive bladder cancer.Frontiers in oncology · 2025Article
- Impact of variant histology in the prognosis of non‑muscle invasive bladder cancer with low‑tumor burden: A propensity score‑matched analysis with conventional urothelial carcinoma.Molecular and clinical oncology · 2024Article
- Giant cell carcinoma of the urinary bladder : Clinicopathologic analysis and oncological outcomes.Virchows Archiv : an international journal of pathology · 2024Article
- Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.BJU international · 2024Article
- Prognostic value of the triglyceride-glucose index in non-muscle-invasive bladder cancer: a retrospective study.Frontiers in nutrition · 2024Article
- circPVT1 Inhibits the Proliferation and Aids in Prediction of the Prognosis of Bladder Cancer.Pharmacogenomics and personalized medicine · 2024Article
- Fluorescence Confocal Microscopy in Urological Malignancies: Current Applications and Future Perspectives.Life (Basel, Switzerland) · 2023Review
- Development and validation of a preoperative nomogram to predict lymph node metastasis in patients with bladder urothelial carcinoma.Journal of cancer research and clinical oncology · 2023Article
- A Validation Study of cT-Categories in the Swedish National Urinary Bladder Cancer Register-Norrland University Hospital.Journal of personalized medicine · 2023Article
- Uncovering the Secrets of Prostate Cancer's Radiotherapy Resistance: Advances in Mechanism Research.Biomedicines · 2023Review
- Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis.Frontiers in surgery · 2023Review
- The relationship between inflammatory response markers and the prognosis of non-muscle invasive bladder cancer and the development of a nomogram model.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The aim of the study was to stratify high-grade T1 (HGT1) bladder urothelial carcinoma into risk categories based on the presence of variant histology when compared to conventional urothelial carcinoma. The clinicopathological features of 104 HGT1 cases of urothelial carcinoma of the bladder with variant histology present in 34 (37%) were assessed. The endpoint of the study was disease-free survival and cancer-specific survival. Overall, variant histology was identified as a significant predictor of disease-free survival (P = 0.035). The presence of any specific variant histology (squamous, glandular, micropapillary, nested, microcystic, inverted growth, villous-like, basaloid, and lymphoepithelioma-like) was identified as a significant predictor of disease-free survival (P = 0.008) and cancer-specific survival (P = 0.0001) in HGT1 bladder cancer. Therefore, our results support including micropapillary HGT1 urothelial carcinoma within the aggressive high-risk category, as suggested by some recent clinical guidelines, but also favor nested, glandular, and basaloid to be placed in the high-risk category due to their potential of aggressive, life-threatening behavior and their limited response to bacillus Calmette-Guerin therapy. Conversely, the low-risk category would include urothelial carcinomas with squamous, inverted growth, or microcystic morphology, all with limited life-threatening potential and good response to current therapy. A very low-risk category would finally include patients whose tumors present villous-like or lymphoepithelioma-like morphology. In conclusion, our findings support the value of reporting the variant histology as a feature of variable aggressiveness in HGT1 urothelial carcinoma of the bladder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.